Covid-19

#Bioscience #Covid-19 #Research

Taconic biosciences launches new Covid-19 mouse model

Taconic Biosciences, providers of animal model solutions for drug discovery, has launched a new Covid-19 mouse model. This human ACE2 (hACE2) transgenic mouse expands Taconic’s Covid-19 research toolkit. In October 2020, Taconic launched its first hACE2 model. The AC70 mouse experiences a lethal response to infection by SARS-CoV-2, the virus… Read More

#Covid-19 #News

#Covid-19 #Pfizer

New President and Vice President of the ABPI announced

The UK Country Manager of Pfizer, Ben Osborn, has been appointed as the new President of the Association of the British Pharmaceutical Industry (ABPI). Pinder Sahota, General Manager of Novo Nordisk, has been appointed as Vice President. Osborn will take over from Hasseb Ahmad and will lead on overseeing… Read More

#News

#Bioban #Biologics #Covid-19 #Life sciences #Thermo Fisher Scientific

Reforming biobanks: from siloes to collaborative powerhouses

By Erik Steinfelder, Biobanking Market Development Director at Thermo Fisher Scientific From hidden repositories, secreted deep in the basements of universities and hospitals, to the emergence of collaborative powerhouses driving ground-breaking therapies, biobanks have come a long way in the past 30 years. Biobanks were originally created as vast repositories… Read More

#Covid-19 #Exclusive Content #News

#Covid-19 #Research

Covid & ethnic minorities: are there differences in immune response

Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 kit will be used for T cell testing in a study being carried out in collaboration with researchers at the University of Leicester. The  DIRECT study (Determining the Immune Response in Ethnic minority healthcare workers to Covid-19 infecTion) is recruiting healthcare workers in Leicester for… Read More

#Covid-19 #News

#Biotechnology #Cell and gene therapy #Covid-19 #Drug delivery #Drug development #Drug technology #Immunology / Virology & Vaccines

Antibody therapeutics: the other race for immunity against SARS-CoV2

Sophie Lutter, OXGENE, looks at the important role antibody therapeutics have to play and how, as the world has looked for Covid-19 treatments in the last year, their significance has been noted. As the world continues to adjust and respond to the impact of the Covid-19 pandemic, the race to… Read More

#Covid-19 #Exclusive Content #News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA #Vaccines

Moderna invests to increase global supply for Covid-19 vaccine

Moderna is to increase supply at its manufacturing facilities, which it expects will increase global 2022 capacity to up to 3 billion doses of its Covid-19 vaccine. This will depend upon the mix between the authorised Moderna Covid-19 vaccine at the 100 μg dose level and potentially lower… Read More

#News

#Covid-19 #Data #Drug delivery #Drug development #Drug discovery #Research

Interim data suggests drug may prevent cytokine storm

Clinical-stage drug development company Noxopharm has announced that in a cohort of 18 patients with moderately severe cases of Covid-19, interim data from its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with the worsening of the virus. “Until enough people are vaccinated to achieve… Read More

#News

#Biopharmaceuticals #Covid-19 #Drug delivery #Drug development #Drug discovery #Drug innovation #Immunology / Virology & Vaccines #Pharma #Pharmaceuticals #Vaccines

Integration at its best: Dalton Pharma outlines its CDMO expertise

Dalton Pharma Services, a contract development and manufacturing organisation (CDMO) offers expertise in drug discovery, formulation and process development, custom synthesis, and GMP manufacturing services. Lu Rahman spoke to CEO, Peter Pekos about the company’s ongoing expertise. LR: The company has experience supplying the needs of the orphan drug field… Read More

#Exclusive Content #News #Opinion

#Covid-19 #Immunology / Virology & Vaccines #Research #Vaccines

Covid-19 vaccine responses to be studied in people with immune deficits

A study assessing how people with immune system deficiencies or dysregulations respond to Covid-19 vaccination has begun enrolling participants at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. The single-site study is led by researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and aims… Read More

#News

#Assay #Assay development optimisation & technology #Covid-19 #Drug development #Immunology / Virology & Vaccines #Reagents

The Native Antigen Company launches assay development kit

The Native Antigen Company has announced the launch of its SARS-CoV-2 Neutralisation Assay Development Kit. The kit can be used to identify and qualitatively assess the ability of antibodies to neutralise SARS-CoV-2-receptor binding, to support research into variants and their effects on natural and vaccine-induced patient immunity. The kit contains… Read More

#News

#AI / data analytics / healthtech / informatics #Augmented reality #Covid-19 #Life sciences #Virtual reality

Virtual and augmented reality – expanding data insights

Insights from data hold the key to understanding how effectively companies are operating and to making connections that lead to discovery and innovation. Recently, software solutions have got better at providing graphical dashboards that help decision-makers visualise their data. In the near future, virtual or augmented reality (VR/AR) technology will… Read More

#Editor's Choice #Exclusive Content #News #Regulatory

#AI / data analytics / healthtech / informatics #Big pharma #Biopharma #Biotechnology #Covid-19 #Drug development #Drug discovery

Waters CEO explains how analytical technologies can assist drug discovery

Udit Batra, CEO of Waters, is known as a listener, learner and gatherer of facts. He talks to Lu Rahman about Waters’ collaboration with pharma and biopharma companies to accelerate vaccine and therapy development as well as the company’s new data analysis technology. LR: We know that the last year… Read More

#Exclusive Content #News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #mRNA #Pfizer #Vaccines

Evonik delivers first lipids to BioNTech ahead of schedule

Chemical specialist Evonik is helping to accelerate the production of the Covid-19 vaccine from Pfizer-BioNTech by suppling an essential component. Evonik is delivering first batches of urgently needed lipids for the mRNA-based vaccine to BioNTech months earlier than anticipated. Specialists at Evonik’s Hanau site set up the lipid production in… Read More

#Covid-19 #News

#Biologics #Cell / tissue culture #Covid-19 #Vaccines

Biden administration unblocks access to federal funded fetal tissue cells

A notice released by the US National Institutes of Health (NIH) on April 16, 2021 revealed that the Biden administration has reversed restrictions set in 2019 by the Trump administration on federal funding for medical research and biomedical studies by government employees using human fetal tissue from elective abortions. Health.com… Read More

#News

#Biologics #Covid-19 #Drug delivery #Gene therapy #Genetics / genomes #Immunology / Virology & Vaccines #RNA

The challenge of providing rapid, effective protection against Covid-19

Lisa Osborne, CEO at RANA Healthcare Solutions interviews Daniel Kavanagh, PhD, Senior Scientific Advisor, Gene Therapy at WCG. The Covid-19 pandemic has put vaccine development centre-stage. Never have citizens around the world been so focused on the length of time it takes to develop, test, approve, manufacture and distribute new… Read More

#Covid-19 #Exclusive Content #News